CB1R expression levels were measured and correlated with neuropathological hallmarks of AD (amyloid-β and tau pathology), neuroinflammatory markers (GFAP and IBA1), cognitive status (Reisberg scale), ApoE genotype, and age. The gene discussed is MAPT; the disease is Alzheimer disease.